There is no “fomo” or `fear of missing out’ when it comes to the GLP-1 category, said Sanofi India Managing Director Deepak Arora, commenting on the intense activity in the domestic diabetes and obesity drugs segment, besides outlining the French healthcare company’s growth plans for India.
Having taken charge a little over a year ago at Sanofi India, Arora has overseen a marketplace that has had to grapple with multiple developments including policy directives on high trade margins on medicine, and the explosion of semaglutide generics —following the expiry of a patent on semaglutide (the active ingredient in Novo’s Ozempic and Wegovy), in markets including India. Sanofi’s Soliqua ensures that the company has “not missed out on GLP-1,” said Arora — as it offers a “unique proposition” combining long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist, in a pre-filled pen, he explains.
But the next chapter for Sanofi India involves “scaling access”, strengthening the rare disease and vaccine portfolio, growing the diabetes products segment and bringing in new products such as haemophilia therapy Qfitlia, (Fitusiran),poised for launch next year, said Arora. Besides the private market, he said, the public sector was also contributing to growth, as Government institutions were also buying innovator drugs. Citing the financial performance of the last quarter, he said, “we had, close to around 85 percent growth come in from the public sector.” This involved health programmes with the ESI, CGHS, army and railway hospitals, he elaborated.
Outlining features available in India for Sanofi India to build on, he said, their manufacturing plant at Goa, had an annual capacity of about five billion tablets, supplying to about 20 countries including India. Over the last 70 years, he said, about 200 trials have been done at 400-odd sites, and presently 18 are underway in future products in segments including multiple sclerosis, COPD/ respiratory, for example. It has its GCC at Hyderabad, with about 4000 people (up from 2600 when it started) — undertaking tasks linked to AI enablement, supporting regulatory pathways across the world, bringing medical information, and compiling data from clinical trials for dossiers for regulatory approvals, he said.
On the trade margin discussions that have taken centre-stage, particularly following recent cases at the Supreme Court, he said, companies have patient support and access programmes for their innovative medicines. Multinationals are already aligned with the trade margins outlined by the Centre, he said, and trade margin rationalisation efforts will provide guardrails, he added.
Published on November 17, 2026




